Consensus and Modeling Guidance
Modeling Guidance
Clariant targets a CAPEX spend of around 220 million Swiss francs in 2024.
Clariant targets to defend a solid investment rating.
Acquisition of Lucas Meyer Cosmetics, closed on 2 April 2024 and added to the Care Chemicals business unit.
- Sales impact 2024 vs. FY 2023: additional ~ CHF 75 m (~ 9 months contribution).
- EBITDA impact 2024 vs. FY 2023: additional ~ CHF 35 m (before CHF 10 million IFRS 3/13 inventory step-up split over Q2 / Q3)
Divestment of Quats business, closed on 1 June 2023 and removed from the Care Chemicals business unit.
- Sales impact 2024 vs. FY 2023: minus ~ CHF 160 m (annualized).
- EBITDA impact 2024 vs. FY 2023: high single- to double-digit million less
Divestment of North American Land Oil business, closed on 31 March 2023 and removed from the Care Chemicals business unit.
- Sales impact 2024 vs. FY 2023: minus ~ CHF 105 m (annualized).
- EBITDA impact 2024 vs. FY 2023: accretive around mid-single digit million
Clariant assumes a tax rate of around 22 %
Clariant targets to create value for shareholders by achieving above-average returns and distributing a stable or rising dividend.
Consensus
Disclaimer: Consensus earnings estimates are based on earnings projections made by equity analysts who cover Clariant. Any opinions, forecasts, estimates, projections or predictions regarding Clariant’s performance made by the analysts (and, therefore, the Consensus estimate numbers) are theirs alone and do not represent the opinions, forecasts, estimates, projections or predictions of Clariant or its management. Clariant does not by providing these estimates imply its endorsement of or concurrence with such information, conclusions or recommendations. Clariant assumes no liability for the accuracy of such estimates and undertakes no obligation to update or revise such estimates.
Contact us
Clariant’s Investor Relations team is committed to an open and fair dialogue with all of its stakeholders. Please contact us.
